Breaking the Crosstalk of the Cellular Tumorigenic Network in NSCLC by a Highly Effective Drug Combination
Guergen, D.; Conrad, T.; Becker, M.; Sebens, S.; Roecken, C.; Hoffmann, J.; Langhammer, S.
Show abstract
Non-small cell lung cancer (NSCLC) is commonly diagnosed at advanced stages limiting treatment options. Although, targeted therapy has become integral part of NSCLC treatment therapies often fail to improve patients prognosis. Based on previously published criteria for selecting drug combinations for overcoming resistances, NSCLC patient-derived xenograft (PDX) tumors were treated with a low dose combination of cabozantinib, afatinib, plerixafor and etoricoxib. All PDX tumors treated, including highly therapy-resistant adeno-and squamous cell carcinomas without identifiable driver mutations, were completely suppressed by this drug regimen, leading to an ORR of 81% and a CBR of 100%. The application and safety profile of this low dose therapy regimen was well manageable in the pre-clinical settings. Overall, this study provides evidence of a relationship between active paracrine signaling pathways of the cellular tumorigenic network, which can be effectively targeted by a low-dose multimodal therapy to overcome therapy resistance and improve prognosis of NSCLC.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer 96%
- A novel role for the tumor suppressor gene ITF2 in lung tumorigenesis and chemotherapy response 96%
- Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data 95%
Similar papers in this journal
- Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in GBM 93%
- Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Cancers Identifies KMT2C as a Potential Tumor Suppressor 93%
- An Evaluation of the Efficacy of Preclinical Models of Lung Cancer Drugs 93%
Similar papers in this journal
- Development and Characterization of Patient-Derived Xenografts from Non-Small Cell Lung Cancer Brain Metastases 94%
- Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma 93%
- Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer 93%
Similar papers in this journal
- An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer 93%
- Molecular diagnosis and prognosis of cancers of unknown-primary (CUPs): progress from a microRNA-based droplet digital PCR assay 93%
- SMARCA4 Mutations in KRAS-mutant Lung Adenocarcinoma: A Multi-cohort Analysis 92%
Similar papers in this journal
- ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer 92%
- SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity 92%
- Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.